AR113827A1 - Composiciones farmacéuticas y métodos para tratar enfermedades cardiovasculares - Google Patents
Composiciones farmacéuticas y métodos para tratar enfermedades cardiovascularesInfo
- Publication number
- AR113827A1 AR113827A1 ARP180103206A ARP180103206A AR113827A1 AR 113827 A1 AR113827 A1 AR 113827A1 AR P180103206 A ARP180103206 A AR P180103206A AR P180103206 A ARP180103206 A AR P180103206A AR 113827 A1 AR113827 A1 AR 113827A1
- Authority
- AR
- Argentina
- Prior art keywords
- histamine
- receptor agonist
- methods
- pharmaceutical compositions
- cardiovascular diseases
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 229940105958 Histamine H2 receptor agonist Drugs 0.000 abstract 2
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 2
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 239000003386 histamine H2 receptor agonist Substances 0.000 abstract 2
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 2
- 229940124241 Histamine H1 receptor agonist Drugs 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 239000003393 histamine H1 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente descripción se proporciona una composición farmacéutica que comprende dos, tres o cuatro compuestos, en donde cada compuesto es independientemente un inhibidor de fosfodiesterasa, un antagonista del receptor de adenosina, un bloqueador de canales de calcio, un agonista del receptor de histamina H₁, un agonista del receptor de histamina H₂, un antagonista del receptor de histamina H₃, o un agonista del receptor adrenérgico b₂. En la presente se proporciona, además, la composición farmacéutica usada para tratar o mejorar una enfermedad cardiovascular en un sujeto, que comprende administrar al sujeto en necesidad de estos dos, tres o cuatro compuestos, en donde cada compuesto es independientemente un inhibidor de fosfodiesterasa, un antagonista del receptor de adenosina, un bloqueador de canales de calcio, un agonista del receptor de histamina H₁, un agonista del receptor de histamina H₂, un antagonista del receptor de histamina H₃, o un agonista del receptor adrenérgico b₂.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762503902P | 2017-05-09 | 2017-05-09 | |
US201862652812P | 2018-04-04 | 2018-04-04 | |
US15/973,132 US11266651B2 (en) | 2017-05-09 | 2018-05-07 | Pharmaceutical compositions and methods of treating cardiovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113827A1 true AR113827A1 (es) | 2020-06-17 |
Family
ID=64096944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103206A AR113827A1 (es) | 2017-05-09 | 2018-11-05 | Composiciones farmacéuticas y métodos para tratar enfermedades cardiovasculares |
Country Status (19)
Country | Link |
---|---|
US (6) | US11266651B2 (es) |
EP (1) | EP3621593A4 (es) |
JP (1) | JP6714796B2 (es) |
KR (1) | KR102197429B1 (es) |
CN (1) | CN109890366B (es) |
AR (1) | AR113827A1 (es) |
AU (1) | AU2018266106B2 (es) |
BR (1) | BR112019023101B1 (es) |
CA (1) | CA3038153C (es) |
CL (1) | CL2019003216A1 (es) |
CO (1) | CO2019010510A2 (es) |
IL (1) | IL269901B (es) |
JO (1) | JOP20190219A1 (es) |
MX (1) | MX2019006233A (es) |
PE (1) | PE20200741A1 (es) |
PH (1) | PH12019502330A1 (es) |
RU (1) | RU2715419C1 (es) |
SG (1) | SG11201902949PA (es) |
WO (1) | WO2018208723A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
US11510924B2 (en) | 2017-05-09 | 2022-11-29 | CARDIX Therapeutics, LLC | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases |
US10582716B1 (en) * | 2019-06-14 | 2020-03-10 | Lennham Pharmaceuticals, Inc. | Deuterated caffeine and uses thereof |
EP4281065A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions |
CN112717092A (zh) * | 2021-01-22 | 2021-04-30 | 行艳丽 | 一种预防心脑血管疾病的中药及制备方法 |
US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
WO2023076547A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Deuterated forms of alkaloid compounds and therapeutic uses thereof |
TW202325275A (zh) | 2021-10-29 | 2023-07-01 | 美商感覺中樞治療公司 | 治療性生物鹼化合物之遞送 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
BR9711585A (pt) | 1996-10-01 | 2000-01-18 | Cima Labs Inc | Composição de microcápsula, com sabor mascarado, de um remédio solúvel em água, formulação farmacêutica para administrar um remédio, e, processo para disfarçar o sabor de um remédio. |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
DK0946169T3 (da) | 1996-12-20 | 2003-04-22 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
RU2115419C1 (ru) | 1997-07-09 | 1998-07-20 | Геннадий Иванович Марков | Лекарственное средство для адсорбционной терапии воспалительных заболеваний слизистых оболочек |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
WO2000000184A2 (en) | 1998-06-26 | 2000-01-06 | Delack Elaine A | Use of histamine h2 mimicking substances for the treatment of multiple sclerosis |
US7001609B1 (en) | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
DE60043318D1 (de) | 1999-08-21 | 2010-01-14 | Nycomed Gmbh | Synergistische kombination von pumafentrine und salmeterol |
BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
US10004684B2 (en) | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
GB2381450B (en) | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
US20050175695A1 (en) | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
JP2008528626A (ja) * | 2005-01-31 | 2008-07-31 | マイラン ラボラトリーズ インク. | ヒドロキシル化されたネビボロールを含む薬学的組成物 |
FR2886150B1 (fr) | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique |
US8207188B2 (en) * | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
WO2008019106A1 (en) | 2006-08-04 | 2008-02-14 | Artesian Therapeutics, Inc. | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
GB201113662D0 (en) | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
KR102150383B1 (ko) | 2016-01-20 | 2020-09-02 | 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 | 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법 |
EP3231417B1 (de) | 2016-04-15 | 2018-12-05 | Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH | Lagerungsstabile, ophthalmische zusammensetzung |
JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
-
2017
- 2017-06-16 JO JOP/2019/0219A patent/JOP20190219A1/ar unknown
-
2018
- 2018-05-07 US US15/973,132 patent/US11266651B2/en active Active
- 2018-05-08 KR KR1020197014692A patent/KR102197429B1/ko active IP Right Grant
- 2018-05-08 MX MX2019006233A patent/MX2019006233A/es unknown
- 2018-05-08 CN CN201880003608.6A patent/CN109890366B/zh active Active
- 2018-05-08 JP JP2019515882A patent/JP6714796B2/ja active Active
- 2018-05-08 EP EP18798353.1A patent/EP3621593A4/en active Pending
- 2018-05-08 BR BR112019023101-3A patent/BR112019023101B1/pt not_active IP Right Cessation
- 2018-05-08 RU RU2019110247A patent/RU2715419C1/ru active
- 2018-05-08 AU AU2018266106A patent/AU2018266106B2/en active Active
- 2018-05-08 CA CA3038153A patent/CA3038153C/en active Active
- 2018-05-08 WO PCT/US2018/031505 patent/WO2018208723A1/en unknown
- 2018-05-08 SG SG11201902949PA patent/SG11201902949PA/en unknown
- 2018-05-08 PE PE2019002140A patent/PE20200741A1/es unknown
- 2018-11-05 AR ARP180103206A patent/AR113827A1/es not_active Application Discontinuation
-
2019
- 2019-03-14 US US16/353,675 patent/US10758544B2/en active Active
- 2019-10-07 IL IL269901A patent/IL269901B/en active IP Right Grant
- 2019-10-11 PH PH12019502330A patent/PH12019502330A1/en unknown
- 2019-11-08 CL CL2019003216A patent/CL2019003216A1/es unknown
- 2019-12-09 CO CONC2019/0010510A patent/CO2019010510A2/es unknown
-
2020
- 2020-08-31 US US17/008,538 patent/US11491159B2/en active Active
-
2022
- 2022-03-08 US US17/689,576 patent/US11878017B2/en active Active
- 2022-11-08 US US18/053,478 patent/US11911389B2/en active Active
-
2024
- 2024-01-23 US US18/420,659 patent/US20240207279A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113827A1 (es) | Composiciones farmacéuticas y métodos para tratar enfermedades cardiovasculares | |
CL2022000922A1 (es) | Aminas bicíclicas como inhibidores de la cdk2. | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
BR112022002698A2 (pt) | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 | |
AR107303A1 (es) | Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit | |
EA202092580A1 (ru) | Соединения, ингибирующие rip1, а также способы их получения и применения | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
BR112022007612A2 (pt) | Inibidores de raf quinases | |
CY1118183T1 (el) | Φαρμακευτικη μορφη δοσης η οποια περιεχει νιφεδιπινη ή νισολδιπινη και εναν ανταγωνιστη αγγειοτενσινης ιι ή/και ενα διουρητικο | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
EA201791955A1 (ru) | ИНГИБИТОРЫ TGF-β | |
BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
ECSP18008922A (es) | Anticuerpos anti-CD154 y métodos de uso de estos | |
BR112018011525A2 (pt) | inibidores da tirosina quinase de bruton e métodos de seu uso | |
EA201692470A1 (ru) | Фармацевтические комбинации | |
BR112017024853A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto | |
BR112017006002A2 (pt) | compostos de imidazopiridazina e seu uso | |
CO2022006466A2 (es) | Inhibidores de egfr alostéricos y métodos de uso de los mismos | |
UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
BR112017013998A2 (pt) | novos derivados de benzimidazol como agentes anti-histamínicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |